Building the drug-GO function network to screen significant candidate drugs for myasthenia gravis.

Myasthenia gravis (MG) is an autoimmune disease. In recent years, considerable evidence has indicated that Gene Ontology (GO) functions, especially GO-biological processes, have important effects on the mechanisms and treatments of different diseases. However, the roles of GO functions in the pathog...

Full description

Bibliographic Details
Main Authors: Shuang Li, Yuze Cao, Lei Li, Huixue Zhang, Xiaoyu Lu, Chunrui Bo, Xiaotong Kong, Zhaojun Liu, Lixia Chen, Peifang Liu, Yang Jiao, Jianjian Wang, Shangwei Ning, Lihua Wang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0214857
id doaj-eb093d3617714193bddd4acb14561b19
record_format Article
spelling doaj-eb093d3617714193bddd4acb14561b192021-03-03T20:45:37ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01144e021485710.1371/journal.pone.0214857Building the drug-GO function network to screen significant candidate drugs for myasthenia gravis.Shuang LiYuze CaoLei LiHuixue ZhangXiaoyu LuChunrui BoXiaotong KongZhaojun LiuLixia ChenPeifang LiuYang JiaoJianjian WangShangwei NingLihua WangMyasthenia gravis (MG) is an autoimmune disease. In recent years, considerable evidence has indicated that Gene Ontology (GO) functions, especially GO-biological processes, have important effects on the mechanisms and treatments of different diseases. However, the roles of GO functions in the pathogenesis and treatment of MG have not been well studied. This study aimed to uncover the potential important roles of risk-related GO functions and to screen significant candidate drugs related to GO functions for MG. Based on MG risk genes, 238 risk GO functions and 42 drugs were identified. Through constructing a GO function network, we discovered that positive regulation of NF-kappaB transcription factor activity (GO:0051092) may be one of the most important GO functions in the mechanism of MG. Furthermore, we built a drug-GO function network to help evaluate the latent relationship between drugs and GO functions. According to the drug-GO function network, 5 candidate drugs showing promise for treating MG were identified. Indeed, 2 out of 5 candidate drugs have been investigated to treat MG. Through functional enrichment analysis, we found that the mechanisms between 5 candidate drugs and associated GO functions may involve two vital pathways, specifically hsa05332 (graft-versus-host disease) and hsa04940 (type I diabetes mellitus). More interestingly, most of the processes in these two pathways were consistent. Our study will not only reveal a new perspective on the mechanisms and novel treatment strategies of MG, but also will provide strong support for research on GO functions.https://doi.org/10.1371/journal.pone.0214857
collection DOAJ
language English
format Article
sources DOAJ
author Shuang Li
Yuze Cao
Lei Li
Huixue Zhang
Xiaoyu Lu
Chunrui Bo
Xiaotong Kong
Zhaojun Liu
Lixia Chen
Peifang Liu
Yang Jiao
Jianjian Wang
Shangwei Ning
Lihua Wang
spellingShingle Shuang Li
Yuze Cao
Lei Li
Huixue Zhang
Xiaoyu Lu
Chunrui Bo
Xiaotong Kong
Zhaojun Liu
Lixia Chen
Peifang Liu
Yang Jiao
Jianjian Wang
Shangwei Ning
Lihua Wang
Building the drug-GO function network to screen significant candidate drugs for myasthenia gravis.
PLoS ONE
author_facet Shuang Li
Yuze Cao
Lei Li
Huixue Zhang
Xiaoyu Lu
Chunrui Bo
Xiaotong Kong
Zhaojun Liu
Lixia Chen
Peifang Liu
Yang Jiao
Jianjian Wang
Shangwei Ning
Lihua Wang
author_sort Shuang Li
title Building the drug-GO function network to screen significant candidate drugs for myasthenia gravis.
title_short Building the drug-GO function network to screen significant candidate drugs for myasthenia gravis.
title_full Building the drug-GO function network to screen significant candidate drugs for myasthenia gravis.
title_fullStr Building the drug-GO function network to screen significant candidate drugs for myasthenia gravis.
title_full_unstemmed Building the drug-GO function network to screen significant candidate drugs for myasthenia gravis.
title_sort building the drug-go function network to screen significant candidate drugs for myasthenia gravis.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2019-01-01
description Myasthenia gravis (MG) is an autoimmune disease. In recent years, considerable evidence has indicated that Gene Ontology (GO) functions, especially GO-biological processes, have important effects on the mechanisms and treatments of different diseases. However, the roles of GO functions in the pathogenesis and treatment of MG have not been well studied. This study aimed to uncover the potential important roles of risk-related GO functions and to screen significant candidate drugs related to GO functions for MG. Based on MG risk genes, 238 risk GO functions and 42 drugs were identified. Through constructing a GO function network, we discovered that positive regulation of NF-kappaB transcription factor activity (GO:0051092) may be one of the most important GO functions in the mechanism of MG. Furthermore, we built a drug-GO function network to help evaluate the latent relationship between drugs and GO functions. According to the drug-GO function network, 5 candidate drugs showing promise for treating MG were identified. Indeed, 2 out of 5 candidate drugs have been investigated to treat MG. Through functional enrichment analysis, we found that the mechanisms between 5 candidate drugs and associated GO functions may involve two vital pathways, specifically hsa05332 (graft-versus-host disease) and hsa04940 (type I diabetes mellitus). More interestingly, most of the processes in these two pathways were consistent. Our study will not only reveal a new perspective on the mechanisms and novel treatment strategies of MG, but also will provide strong support for research on GO functions.
url https://doi.org/10.1371/journal.pone.0214857
work_keys_str_mv AT shuangli buildingthedruggofunctionnetworktoscreensignificantcandidatedrugsformyastheniagravis
AT yuzecao buildingthedruggofunctionnetworktoscreensignificantcandidatedrugsformyastheniagravis
AT leili buildingthedruggofunctionnetworktoscreensignificantcandidatedrugsformyastheniagravis
AT huixuezhang buildingthedruggofunctionnetworktoscreensignificantcandidatedrugsformyastheniagravis
AT xiaoyulu buildingthedruggofunctionnetworktoscreensignificantcandidatedrugsformyastheniagravis
AT chunruibo buildingthedruggofunctionnetworktoscreensignificantcandidatedrugsformyastheniagravis
AT xiaotongkong buildingthedruggofunctionnetworktoscreensignificantcandidatedrugsformyastheniagravis
AT zhaojunliu buildingthedruggofunctionnetworktoscreensignificantcandidatedrugsformyastheniagravis
AT lixiachen buildingthedruggofunctionnetworktoscreensignificantcandidatedrugsformyastheniagravis
AT peifangliu buildingthedruggofunctionnetworktoscreensignificantcandidatedrugsformyastheniagravis
AT yangjiao buildingthedruggofunctionnetworktoscreensignificantcandidatedrugsformyastheniagravis
AT jianjianwang buildingthedruggofunctionnetworktoscreensignificantcandidatedrugsformyastheniagravis
AT shangweining buildingthedruggofunctionnetworktoscreensignificantcandidatedrugsformyastheniagravis
AT lihuawang buildingthedruggofunctionnetworktoscreensignificantcandidatedrugsformyastheniagravis
_version_ 1714820836525867008